Therapy Monitoring & Companion Diagnostic Services
Multiple Cancers
Service OfferingActive
Key Facts
About Creatv Bio
Creatv Bio is a private diagnostics company pioneering a liquid biopsy platform focused on detecting large, phagocytic circulating cells called Cancer Associated Macrophage-Like Cells (CAMLs). Its core value proposition is the potential for early cancer detection and recurrence monitoring across more than 30 cancer types, using a standard blood draw. The company operates in both the clinical research and biopharma services markets, offering assays for patient stratification, therapy monitoring, and drug development support. Its technology differentiates by targeting CAMLs, which are present from early-stage disease, unlike traditional CTCs often found only in later stages.
View full company profileTherapeutic Areas
Other Multiple Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Targeted Immuno-Oncology Gene Therapy | Scopus BioPharma | Pre-clinical |
| CAML/CTC Assay for MRD & Recurrence | Creatv Bio | Clinical Research |
| Biopharma MRD-Guided Trial Services | Natera | Collaborative Development |